A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Non-Hodgkin's Lymphoma
- Registration Number
- NCT00038545
- Lead Sponsor
- M.D. Anderson Cancer Center
- Brief Summary
For patients with relapsed and refractory aggressive non-Hodgkin's lymphoma
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
UT MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
UT MD Anderson Cancer Center🇺🇸Houston, Texas, United States